MannKind Slips on Unexpected 4Q Loss

Dow Jones

Feb 27

By Katherine Hamilton

Shares of MannKind fell after the biopharmaceutical company posted an unexpected loss in the fourth quarter.

The stock slid 9.3%, to $3.18, Thursday afternoon, at one point touching a 52-week low of $2.94. Shares have lost 42% of their value over the past 12 months.

The Danbury, Conn., company swung to a loss of $15.9 million, or 5 cents a share, from a profit of $7.4 million, or 3 cents a share, the year before.

Cost of goods sold nearly tripled in the quarter, primarily due to the inclusion of Furoscix following its acquisition in October.

Research-and-development expenses more than doubled partly due to the Icon-1 clinical study for MNKD-101, which was discontinued in the fourth quarter.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

February 26, 2026 15:19 ET (20:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614073569"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614073569\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614073569?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614073569","market":"nz","top_or_hot":-1,"title":"MannKind Slips on Unexpected 4Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of MannKind fell after the biopharmaceutical company posted an unexpected loss in the fourth quarter. \n</p>\n<p>\n  The stock slid 9.3%, to $3.18, Thursday afternoon, at one point touching a 52-week low of $2.94. Shares have lost 42% of their value over the past 12 months. \n</p>\n<p>\n  The Danbury, Conn., company swung to a loss of $15.9 million, or 5 cents a share, from a profit of $7.4 million, or 3 cents a share, the year before. \n</p>\n<p>\n  Cost of goods sold nearly tripled in the quarter, primarily due to the inclusion of Furoscix following its acquisition in October. \n</p>\n<p>\n  Research-and-development expenses more than doubled partly due to the Icon-1 clinical study for MNKD-101, which was discontinued in the fourth quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2026 15:19 ET (20:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind Slips on Unexpected 4Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind Slips on Unexpected 4Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-27 04:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of MannKind fell after the biopharmaceutical company posted an unexpected loss in the fourth quarter. \n</p>\n<p>\n  The stock slid 9.3%, to $3.18, Thursday afternoon, at one point touching a 52-week low of $2.94. Shares have lost 42% of their value over the past 12 months. \n</p>\n<p>\n  The Danbury, Conn., company swung to a loss of $15.9 million, or 5 cents a share, from a profit of $7.4 million, or 3 cents a share, the year before. \n</p>\n<p>\n  Cost of goods sold nearly tripled in the quarter, primarily due to the inclusion of Furoscix following its acquisition in October. \n</p>\n<p>\n  Research-and-development expenses more than doubled partly due to the Icon-1 clinical study for MNKD-101, which was discontinued in the fourth quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2026 15:19 ET (20:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614073569","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614073569","pubTimestamp":1772137140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of MannKind fell after the biopharmaceutical company posted an unexpected loss in the fourth quarter.The stock slid 9.3%, to $3.18, Thursday afternoon, at one point touching a 52-week low of $2.94. Shares have lost 42% of their value over the past 12 months.The Danbury, Conn., company swung to a loss of $15.9 million, or 5 cents a share, from a profit of $7.4 million, or 3 cents a share, the year before.Cost of goods sold nearly tripled in the quarter, primarily due to the inclusion of Furoscix following its acquisition in October.Research-and-development expenses more than doubled partly due to the Icon-1 clinical study for MNKD-101, which was discontinued in the fourth quarter.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","MNKD":"曼恩凯德生物医疗","BK4139":"生物科技"},"translate_title":"MannKind因第四季度意外亏损而下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of MannKind fell after the biopharmaceutical company posted an unexpected loss in the fourth quarter. \n\n\n  The stock slid 9.3%, to $3.18, Thursday afternoon, at one point touching a 52-week low of $2.94. Shares have lost 42% of their value over the past 12 months. \n\n\n  The Danbury, Conn., company swung to a loss of $15.9 million, or 5 cents a share, from a profit of $7.4 million, or 3 cents a share, the year before. \n\n\n  Cost of goods sold nearly tripled in the quarter, primarily due to the inclusion of Furoscix following its acquisition in October. \n\n\n  Research-and-development expenses more than doubled partly due to the Icon-1 clinical study for MNKD-101, which was discontinued in the fourth quarter. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2026 15:19 ET (20:19 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}